WADA Independent Observer Report Olympic Games 2000 Sydney, Australia / Harri Syväsalmi. - Independent Observer Team. - World Anti-Doping Agency (WADA), 2000

Contents:

- Introduction
- Laboratory
- Doping Control Command Centre
- Doping Control Stations
- Doping Control Officers
- Doping Control Procedures
- Courier
- Recommendations
- Annex 1. Medical Report
- Annex 2. Laboratory Report
- Annex 3. Result Management
- Appendices:
- IO Terms of Reference
- Confidentiality Document
- Conflict of Interest Doc
- IO Team
- Observation Summary

Report of the Independent Observers 19th Asian Games
Hangzhou, China 2022 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2024

Report of the Independent Observers XVIII Asian Games Jakarta Palembang 2018 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2019

WADA Independent Observer Mission Report 16th Asian Games Guangzhou, China November 2010 / Independent Observer Team. - Montreal : World Anti-Doping Agency (WADA), 2010

2022 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2024

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report - pp. 10-39 (30 pages)
• Sport Report - pp. 40-155 (116 pages)
• Testing Authority Report - pp. 156-279 (124 pages)
• ABP Report-Blood Analysis - pp. 280-320 (41 pages)

Report Highlights:

• A 6.4% increase in the total number of samples (including urine, non-ABP blood and dried blood spot samples) analyzed and reported into ADAMS in 2022 (256,770) vs. 2021 (241,430); 

• An increase in the total percentage of AAFs year on year; 

• An increase in the total number of samples analyzed and reported by most WADA-accredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021. 

• An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022.  

• An increase of 1.4% in the number of ABP blood samples analyzed in 2022. 

• An increase in the total number of AAFs and % AAF for ERAs [including erythropoietin (EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022.  

The World Anti-Doping Agency (WADA) has published its 2022 Testing Figures Report (2022 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2022. 

The 2022 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs). 

2021 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2023

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report -– pp. 10-39 (30 pages)
• Sport Report - pp. 40-153 (114 pages)
• Testing Authority Report - pp. 154-267 (114 pages)
• ABP Report-Blood Analysis - pp. 268-311 (44 pages)

Report Highlights:

• A 61.2% increase in the number of samples (both urine and non-ABP blood samples) analyzed
  and reported into ADAMS: 149,758 in 2020 to 241,430 in 2021.
• An increase in the total number of samples analyzed and reported by nearly all WADAaccredited
  laboratories and WADA-approved laboratories into ADAMS in 2021 compared to 2020.
• An increase in the total number and percentage of non-ABP blood samples analyzed: 7.3%
  (10,940 of 149,758 samples) in 2020 to 9.3% (22,398 Blood + DBS samples out of 241,430).
• An increase of 36% in the number of ABP blood samples analyzed: 22,666 in 2020 to 30,821
  in 2021.
• A decrease in the total percentage of AAFs: 0.67% in 2020 (1,009 AAFs from 149,758
  samples) to 0.65% (1,560 AAFs from 241,430 samples).
• An increase in the total number of AAFs for growth hormone (GH): 1 in 2020 to 7 in 2021,
  including the first reported AAF for a GH biomarker.
• A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
• A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
• All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
• A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
• A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.

The World Anti-Doping Agency (WADA) has publishes its 2021 Testing Figures Report (2021 Report), which summarizes the results of all the samples WADA-accredited laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2021.

This is the first set of global testing figures under the 2021 World Anti-Doping Code (Code) that came into effect in January 2021. The 2021 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples, blood and ABP blood data, and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).

2020 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2021

Contents:

• Executive Summary - pp. 2-9 (7 pages)
• Laboratory Report -– pp. 10-36 (27 pages)
• Sport Report - pp. 37-137 (101 pages)
• Testing Authority Report - pp. 138-244 (107 pages)
• ABP Report-Blood Analysis - pp. 245-279 (35 pages)

Report Highlights:

• A 46% decrease in the overall number of samples analyzed: 278,047 in 2019 to 149,758 in 2020.
• A decrease in the total percentage of Adverse Analytical Findings (AAFs): 0.97% in 2019 (2,702 AAFs from 278,047 samples) to 0.67% in 2020 (1,009 AAFs from 149,758 samples).
• All WADA-accredited Laboratories saw a decrease in the total number of samples recorded.
• A decrease in the total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.1% in 2019 (25,339 of 278,047) and 7.3% (10,940 of 149,758) in 2020.
• A decrease of 38% in the number of ABP blood samples tested: 36,401 in 2019 to 22,666 in 2020.

The World Anti-Doping Agency (WADA) has publishes its 2020 Testing Figures Report (2020 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2020.

This is the sixth and last set of global testing figures under the 2015 World Anti-Doping Code (Code) that came into effect in January 2015. The 2020 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs).

2019 Anti-Doping Testing Figures / World Anti-Doping Agency (WADA). - Montreal : WADA, 2020

Contents:

• Executive Summary - pp. 2-8 (7 pages)
• Laboratory Report -– pp. 9-37 (28 pages)
• Sport Report - pp. 38-174 (137 pages)
• Testing Authority Report - pp. 175-313 (139 pages)
• ABP Report-Blood Analysis - pp. 314-355 (42 pages)

Report Highlights

• A 5.5% increase in the overall number of samples analyzed: 263,519 in 2018 to 278,047 in 2019.
• A slight decrease in the total percentage of Adverse Analytical Findings (AAFs): 1.05% in 2018 (2,774 AAFs from 263,519 samples) to 0.97% in 2019 (2,702 AAFs from 278,047 samples).
• About 60% of WADA-accredited Laboratories saw an increase in the total number of samples recorded.
• An almost similar total number and percentage of non-Athlete Biological Passport (ABP) blood samples analyzed: 9.3% in 2018 (24,495 of 263,519) and 9.1% in 2019 (25,339 of 278,047).
• An increase of 16% in the number of ABP blood samples tested: 31,265 in 2018 to 36,401 in 2019.
• An increase in AAFs reported for Erythropoiesis Stimulating Agents (ESAs), Growth Hormone (GH) and Growth Hormone Releasing Factors (GHRFs).

The World Anti-Doping Agency (WADA) has published its 2019 Testing Figures Report (2019 Report), which summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported in WADA’s Anti-Doping Administration and Management System (ADAMS) in 2019.

This is the fifth set of global testing figures under the version of the World Anti-Doping Code (Code) that came into effect in January 2015. The 2019 Report – which includes an Executive Summary and sub-reports by Laboratory, Sport, Testing Authority and Athlete Biological Passport (ABP) Blood Analysis – includes in- and out-of-competition urine samples; blood and ABP blood data; and, the resulting AAFs and Atypical Findings (ATFs).